ClinicalTrials.gg
Drug

Depatuxizumab mafodotin clinical trials

Also written ABT-414.

studies test it
7
open now
0
in phase 3
2
first study started
2012

How each study uses depatuxizumab mafodotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Depatuxizumab mafodotin
4

Development codes

ABT-414
6
ABBV-221
1

Studies by the year they started

7 studies that test it; most in 2015 (4)

Studies that test depatuxizumab mafodotin, by start year
YearStudies
20121
20131
20154
20181

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
2
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 7 · Other 0

AbbVie (6) · AbbVie (prior sponsor, Abbott) (1)

Often tested with

Tested in the same studies.

Temozolomide (1)

Studies

Open first, then newest update. How each study uses depatuxizumab mafodotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 7

Codes

What other systems call depatuxizumab mafodotin · ClinicalTrials.gg INT001111

  • MeSH (NLM) C000631685depatuxizumab mafodotinOne source NLM
  • UNII (FDA) F3R7A4P04NDEPATUXIZUMAB MAFODOTINConfirmed FDA, NLM, Wikidata
  • Wikidata Q28209069depatuxizumab mafodotinConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C105612Depatuxizumab MafodotinOne source FDA
  • DrugBank DB11731One source Wikidata

Also registered as losatuxizumab vedotin (UNII 17C83BVV62).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.